NOVAVAX to Present at Lazard 7th Annual Healthcare Conference
ROCKVILLE, Md., Nov. 11, 2010 /PRNewswire via COMTEX/ --
Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biopharmaceutical company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax will be presenting at the Lazard 7th Annual Healthcare Conference. The presentation will take place on Tuesday, November 16, 2010 at 1:10pm local time at the St. Regis Hotel, New York, NY. An audio link to the live presentation can be accessed via the Company website at www.novavax.com under Investors/Events. An archive of the presentation will be available after the event on the Novavax website for 90 days.
Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.
SOURCE Novavax, Inc.